Treatment of metastatic cervical cancer: Future directions involving targeted agents

Critical Reviews in Oncology/Hematology

Volumn 85, Issue 3, 2013, Pages 303-314

  Diaz Padilla, Ivan ^a,b   Monk, Bradley J ^c   Mackay, Helen J ^a   Oaknin, Ana ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b Hospital Universitario Madrid   (Spain)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Angiogenesis; Clinical trial; Human papilloma virus; Metastatic cervical cancer; Targeted therapy

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADXS 001; ANGIOPOIETIN; BEVACIZUMAB; BRIVANIB; CANCER VACCINE; CEDIRANIB; CETUXIMAB; CISPLATIN; CVX 060; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MAPATUMUMAB; MK 1775; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; PACLITAXEL; PAZOPANIB; PF 4856884; SUNITINIB; TEMSIROLIMUS; TOPOTECAN; TREBANANIB; UNCLASSIFIED DRUG; VELIPARIB;

ABDOMINAL PAIN; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE; CELL CYCLE REGULATION; DIARRHEA; DRUG RESPONSE; ENZYME INHIBITION; FATIGUE; FISTULA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INNATE IMMUNITY; INTESTINE PERFORATION; METASTASIS POTENTIAL; NAUSEA; PAIN; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; THROMBOSIS; UPREGULATION; URINARY TRACT FISTULA; UTERINE CERVIX CANCER; WART VIRUS;

FEMALE; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; UTERINE CERVICAL NEOPLASMS;

EID: 84873527086     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.07.006     Document Type: Review

References (106)

1. Monk B.J., Herzog T.J. The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination. American Journal of Obstetrics and Gynecology 2007, 197:337-339.
2. Waggoner S.E. Cervical cancer. Lancet 2003, 361:2217-2225.
3. Moore D.H., Blessing J.A., McQuellon R.P., et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2004, 22:3113-3119.
4. McQuellon R.P., Thaler H.T., Cella D., Moore D.H. Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecologic Oncology 2006, 101:296-304.
5. Monk B.J., Sill M.W., McMeekin D.S., et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2009, 27:4649-4655.
6. Lorusso D., Pietragalla A., Mainenti S., Masciullo V., Di Vagno G., Scambia G. Review role of topotecan in gynaecological cancers: current indications and perspectives. Critical Reviews in Oncology/Hematology 2010, 74:163-174.
7. Wang S.S., Sherman M.E., Hildesheim A., Lacey J.V., Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 2004, 100:1035-1044.
8. Bray F., Carstensen B., Moller H., et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiology, Biomarkers and Prevention 2005, 14:2191-2199.
9. Sherman M.E., Wang S.S., Carreon J., Devesa S.S. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer 2005, 103:1258-1264.
10. Gien L.T., Beauchemin M.C., Thomas G. Adenocarcinoma: a unique cervical cancer. Gynecologic Oncology 2010, 116:140-146.
11. Wright A.A., Hirsch M.S., Wagle N., et al. KRAS and EGFR mutations to distinguish adenocarcinomas and squamous cell carcinomas of the cervix. Journal of Clinical Oncology 2012, 30:5011.
12. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology 2002, 55:244-265.
13. Narisawa-Saito M., Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Science 2007, 98:1505-1511.
14. Patel D., Incassati A., Wang N., McCance D.J. Human papillomavirus type 16 E6 and E7 cause polyploidy in human keratinocytes and up-regulation of G2-M-phase proteins. Cancer Research 2004, 64:1299-1306.
15. Nakamura M., Bodily J.M., Beglin M., Kyo S., Inoue M., Laimins L.A. Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses. Virology 2009, 387:442-448.
16. Kim M.K., Kim H.S., Kim S.H., et al. Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment. Biochemical Pharmacology 2010, 80:1930-1935.
17. DiMaio D., Mattoon D. Mechanisms of cell transformation by papillomavirus E5 proteins. Oncogene 2001, 20:7866-7873.
18. Smith-McCune K.K., Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Research 1994, 54:800-804.
19. Kodama J., Seki N., Tokumo K., et al. Vascular endothelial growth factor is implicated in early invasion in cervical cancer. European Journal of Cancer 1999, 35:485-489.
20. Willmott L.J., Monk B.J. Cervical cancer therapy: current, future and anti-angiogensis targeted treatment. Expert Review of Anticancer Therapy 2009, 9:895-903.
21. Santin A.D., Hermonat P.L., Ravaggi A., Pecorelli S., Cannon M.J., Parham G.P. Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstetrics and Gynecology 1999, 94:78-82.
22. Bachtiary B., Selzer E., Knocke T.H., Potter R., Obermair A. Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival. Cancer Letters 2002, 179:197-203.
23. Lee I.J., Park K.R., Lee K.K., et al. Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix. International Journal of Radiation Oncology, Biology, Physics 2002, 54:768-779.
24. Loncaster J.A., Cooper R.A., Logue J.P., Davidson S.E., Hunter R.D., West C.M. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. British Journal of Cancer 2000, 83:620-625.
25. Mitsuhashi A., Suzuka K., Yamazawa K., Matsui H., Seki K., Sekiya S. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer 2005, 103:724-730.
26. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2004, 350:2335-2342.
27. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine 2006, 355:2542-2550.
28. Monk B.J., Sill M.W., Burger R.A., Gray H.J., Buekers T.E., Roman L.D. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2009, 27:1069-1074.
29. Tewari K.S., Monk B.J. Gynecologic Oncology Group trials of chemotherapy for metastatic and recurrent cervical cancer. Current Oncology Reports 2005, 7:419-434.
30. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Research 2003, 9:327-337.
31. Mackay H.J., Tinker A., Winquist E., et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecologic Oncology 2010, 116:163-167.
32. Hurwitz H.I., Dowlati A., Saini S., et al. Phase I trial of pazopanib in patients with advanced cancer. Clinical Cancer Research 2009, 15:4220-4227.
33. Monk B.J., Mas Lopez L., Zarba J.J., et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology 2010, 28:3562-3569.
34. Monk B.J., Pandite L.N. Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology 2011, 29:4845.
35. Diaz-Padilla I., Siu L.L. Brivanib alaninate for cancer. Expert Opinion on Investigational Drugs 2011, 20:577-586.
36. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine and Growth Factor Reviews 2005, 16:159-178.
37. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nature Reviews Cancer 2010, 10:116-129.
38. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
39. Bhide R.S., Lombardo L.J., Hunt J.T., et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Molecular Cancer Therapeutics 2010, 9:369-378.
40. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer 2008, 8:592-603.
41. Huang H., Bhat A., Woodnutt G., Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nature Reviews Cancer 2010, 10:575-585.
42. Nasarre P., Thomas M., Kruse K., et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Research 2009, 69:1324-1333.
43. Shim W.S., Teh M., Bapna A., et al. Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Experimental Cell Research 2002, 279:299-309.
44. Scambia G., Ferrandina G., Distefano M., D'Agostino G., Benedetti-Panici P., Mancuso S. Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer. Cancer Letters 1998, 123:135-139.
45. Kersemaekers A.M., Fleuren G.J., Kenter G.G., et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clinical Cancer Research 1999, 5:577-586.
46. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. European Journal of Cancer 2001, Suppl 4(37):S9-S15.
47. Sequist L.V., Martins R.G., Spigel D., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Journal of Clinical Oncology 2008, 26:2442-2449.
48. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine 2004, 350:2129-2139.
49. Arias-Pulido H., Joste N., Chavez A., et al. Absence of epidermal growth factor receptor mutations in cervical cancer. International Journal of Gynecological Cancer 2008, 18:749-754.
50. Schilder R.J., Sill M.W., Lee Y.C., Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. International Journal of Gynecological Cancer 2009, 19:929-933.
51. Goncalves A., Fabbro M., Lhomme C., et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecologic Oncology 2008, 108:42-46.
52. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Medicine 2000, 6:443-446.
53. Prewett M., Rothman M., Waksal H., Feldman M., Bander N.H., Hicklin D.J. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clinical Cancer Research 1998, 4:2957-2966.
54. Bellone S., Frera G., Landolfi G., et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecologic Oncology 2007, 106:513-520.
55. Vermorken J.B., Mesia R., Rivera F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. New England Journal of Medicine 2008, 359:1116-1127.
56. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England Journal of Medicine 2004, 351:337-345.
57. Farley J., Sill M.W., Birrer M., et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecologic Oncology 2011, 121:303-308.
58. Santin A.D., Sill M.W., McMeekin D.S., et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecologic Oncology 2011, 122:495-500.
59. Kurtz J.E., Hardy-Bessard A.C., Deslandres M., et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial. Gynecologic Oncology 2009, 113:16-20.
60. Zhang X.Y., Zhang H.Y., Zhang P.N., Lu X., Sun H. Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2008, 139:237-244.
61. Feng W., Duan X., Liu J., Xiao J., Brown R.E. Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. International Journal of Clinical and Experimental Pathology 2009, 2:249-260.
62. Heselmeyer K., Schrock E., du Manoir S., et al. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:479-484.
63. Lu Z., Hu X., Li Y., et al. Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. Journal of Biological Chemistry 2004, 279:35664-35670.
64. Oh K.J., Kalinina A., Park N.H., Bagchi S. Deregulation of eIF4E: 4E-BP1 in differentiated human papillomavirus-containing cells leads to high levels of expression of the E7 oncoprotein. Journal of Virology 2006, 80:7079-7088.
65. Hall A.H., Alexander K.A. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. Journal of Virology 2003, 77:6066-6069.
66. Tinker A.M.H., Ellard S., Welch S., Eisenhauer E. Preliminary activity of temsirolimus, an mTOR inhibitor, in patients with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix: a NCIC-CTG Phase II Clinical Trial. Molecular Cancer Therapeutics 2011.
67. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411:366-374.
68. Ame J.C., Spenlehauer C., de Murcia G. The PARP superfamily. Bioessays 2004, 26:882-893.
69. Pulido H.A., Fakruddin M.J., Chatterjee A., et al. Identification of a 6-cM minimal deletion at 11q23.1-23.2 and exclusion of PPP2R1B gene as a deletion target in cervical cancer. Cancer Research 2000, 60:6677-6682.
70. Narayan G., Arias-Pulido H., Nandula S.V., et al. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Research 2004, 64:2994-2997.
71. Marsit C.J., Liu M., Nelson H.H., Posner M., Suzuki M., Kelsey K.T. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004, 23:1000-1004.
72. Malumbres M., Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nature Reviews Cancer 2009, 9:153-166.
73. Dixon H., Norbury C.J. Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle 2002, 1:362-368.
74. Iorns E., Lord C.J., Grigoriadis A., et al. Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One 2009, 4:e5120.
75. Wang Y., Decker S.J., Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biology and Therapy 2004, 3:305-313.
76. Hirai H., Iwasawa Y., Okada M., et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Molecular Cancer Therapeutics 2009, 8:2992-3000.
77. Palmer B.D., Smaill J.B., Rewcastle G.W., et al. Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1. Bioorganic and Medicinal Chemistry Letters 2005, 15:1931-1935.
78. Palmer B.D., Thompson A.M., Booth R.J., et al. 4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution. Journal of Medicinal Chemistry 2006, 49:4896-4911.
79. Smaill J.B., Baker E.N., Booth R.J., et al. Synthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases. European Journal of Medical Chemistry 2008, 43:1276-1296.
80. Smaill J.B., Lee H.H., Palmer B.D., et al. Synthesis and structure-activity relationships of soluble 8-substituted 4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinases. Bioorganic and Medicinal Chemistry Letters 2008, 18:929-933.
81. Schellens J.H.M., Shapiro G., Pavlick A.C., et al. Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. American Society of Clinical Oncology Meeting Abstracts 2011, 29:3068.
82. Werness B.A., Levine A.J., Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990, 248:76-79.
83. Lin Z., Bazzaro M., Wang M.C., Chan K.C., Peng S., Roden R.B. Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clinical Cancer Research 2009, 15:570-577.
84. Ashkenazi A., Holland P., Eckhardt S.G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). Journal of Clinical Oncology 2008, 26:3621-3630.
85. Hougardy B.M., Maduro J.H., van der Zee A.G., et al. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. International Journal of Cancer 2006, 118:1892-1900.
86. Pukac L., Kanakaraj P., Humphreys R., et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. British Journal of Cancer 2005, 92:1430-1441.
87. Hotte S.J., Hirte H.W., Chen E.X., et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clinical Cancer Research 2008, 14:3450-3455.
88. Tolcher A.W., Mita M., Meropol N.J., et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. Journal of Clinical Oncology 2007, 25:1390-1395.
89. Greco F.A., Bonomi P., Crawford J., et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008, 61:82-90.
90. Molling J.W., de Gruijl T.D., Glim J., et al. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. International Journal of Cancer 2007, 121:1749-1755.
91. Monnier-Benoit S., Mauny F., Riethmuller D., et al. Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix. Gynecologic Oncology 2006, 102:22-31.
92. Bhat P., Mattarollo S.R., Gosmann C., Frazer I.H., Leggatt G.R. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunological Reviews 2011, 239:85-98.
93. Tuve S., Chen B.M., Liu Y., et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Research 2007, 67:5929-5939.
94. Calabro L., Danielli R., Sigalotti L., Maio M. Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Seminars in Oncology 2010, 37:460-467.
95. Souders N.C., Sewell D.A., Pan Z.K., et al. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immunity 2007, 7:2.
96. Maciag P.C., Radulovic S., Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009, 27:3975-3983.
97. Morelli M.P., Calvo E., Ordonez E., et al. Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. Journal of Clinical Oncology 2012, 30:e45-e48.
98. Hidalgo M., Bruckheimer E., Rajeshkumar N.V., et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Molecular Cancer Therapeutics 2011, 10:1311-1316.
99. Scotto L., Narayan G., Nandula S.V., et al. Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes, Chromosomes and Cancer 2008, 47:755-765.
100. Scotto L., Narayan G., Nandula S.V., et al. Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. Molecular Cancer 2008, 7:58.
101. Seymour L., Ivy S.P., Sargent D., et al. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clinical Cancer Research 2010, 16:1764-1769.
102. Brader K.R., Morris M., Levenback C., Levy L., Lucas K.R., Gershenson D.M. Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design. Journal of Clinical Oncology 1998, 16:1879-1884.
103. Dhani N., Tu D., Sargent D.J., Seymour L., Moore M.J. Alternate endpoints for screening phase II studies. Clinical Cancer Research 2009, 15:1873-1882.
104. El-Maraghi R.H., Eisenhauer E.A. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. Journal of Clinical Oncology 2008, 26:1346-1354.
105. Davidson S. Treatment for advanced cervical cancer: impact on quality of life. Critical Reviews in Oncology/Hematology 2011, 79:24-30.
106. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. Journal of Clinical Oncology 2006, 24:2137-2150.